198 related articles for article (PubMed ID: 27751981)
21. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
22. [A scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase receiving initial imatinib therapy].
Li ZY; Zhang MY; Zhang XS; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):106-111. PubMed ID: 36948863
[No Abstract] [Full Text] [Related]
23. Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.
Ganguly S; Lakshmaiah KC; Jacob LA; Babu S; Dasappa L; Govind Babu KS
Indian J Hematol Blood Transfus; 2017 Mar; 33(1):82-86. PubMed ID: 28194061
[TBL] [Abstract][Full Text] [Related]
24. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
Gurrea Salas D; Glauche I; Tauer JT; Thiede C; Suttorp M
Ann Hematol; 2015 Aug; 94(8):1363-71. PubMed ID: 25894600
[TBL] [Abstract][Full Text] [Related]
25. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Leuk Lymphoma; 2018 May; 59(5):1105-1112. PubMed ID: 28838287
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
27. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
Tiribelli M; Bonifacio M; Calistri E; Binotto G; Maino E; Marin L; Guardalben E; Branca A; Gherlinzoni F; Semenzato G; Sancetta R; Pizzolo G; Fanin R
Leuk Res; 2013 Nov; 37(11):1457-60. PubMed ID: 23993428
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
29. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.
Yang X; Bai Y; Shi M; Zhang W; Niu J; Wu C; Zhang L; Xu Z; Liu X; Chen Y; Sun K
Cancer Manag Res; 2020; 12():1293-1301. PubMed ID: 32110103
[TBL] [Abstract][Full Text] [Related]
30. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
[TBL] [Abstract][Full Text] [Related]
31. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
[TBL] [Abstract][Full Text] [Related]
32. [The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].
Bao X; Qiu H; Chen S; Ma X; Tang X; Fu C; Sun A; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):553-8. PubMed ID: 26304076
[TBL] [Abstract][Full Text] [Related]
33. Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
Heinrichs A; Dessars B; El Housni H; Pluymers W; Peeters K; Benghiat FS; Heimann P
Leuk Res; 2018 Apr; 67():27-31. PubMed ID: 29425962
[TBL] [Abstract][Full Text] [Related]
34. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
[TBL] [Abstract][Full Text] [Related]
35. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Hasford J; Baccarani M; Hoffmann V; Guilhot J; Saussele S; Rosti G; Guilhot F; Porkka K; Ossenkoppele G; Lindoerfer D; Simonsson B; Pfirrmann M; Hehlmann R
Blood; 2011 Jul; 118(3):686-92. PubMed ID: 21536864
[TBL] [Abstract][Full Text] [Related]
36. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
37. Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.
Qin YZ; Jiang Q; Jiang H; Lai YY; Zhu HH; Liu YR; Jiang B; Huang XJ
Medicine (Baltimore); 2016 Jan; 95(2):e2486. PubMed ID: 26765457
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
39. Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy.
Al-Ghazaly J; Al-Dubai W; Noaman Y; Abdullah M; Al-Gharasi L; Rosti G
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):e144-e153. PubMed ID: 31983635
[TBL] [Abstract][Full Text] [Related]
40. Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
Molica M; Colafigli G; Scalzulli E; Alunni Fegatelli D; Chiatamone Ranieri S; Rizzo L; Diverio D; Efficace F; Latagliata R; Foà R; Breccia M
Ann Hematol; 2019 Aug; 98(8):1891-1904. PubMed ID: 31079264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]